In which cases would you use adjuvant abemaciclib for a patient with extensive residual disease that is triple-positive (ER+PR+HER2+) following neoadjuvant TCHP?
1 Answers
Mednet Member
Medical Oncology · University of Hawai'i Cancer Center
There is no evidence that adjuvant abemaciclib benefits the HR+ HER2+ setting. The biology between HR+ HER+ and HR- HER2+ is quite different.
In which cases would you use adjuvant abemaciclib for a patient with extensive residual disease that is triple-positive (ER+PR+HER2+) following neoadjuvant TCHP? | Mednet
